Galux teams with GC Biopharma to fast-track AI antibody drugs

Galux, an AI-driven biotech startup specializing in de novo antibody design, said Tuesday it has partnered with GC Biopharma to develop antibody therapeutics for autoimmune diseases. Under the agreement, Galux will deploy its proprietary artificial intelligence platform to design novel antibody candidates optimized for disease-related target proteins, while GC Biopharma will carry out experimental validation to assess biological activity and development potential. The two companies plan to scree

By The Korea Herald